Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis for at least 6 months prior to enrollment~* At least 10% BSA of psoriasis at screening and at enrollment~* sPGA score of at least 3 and PASI score of at least 12 at screening and at enrollment~* Candidates for phototherapy and/or systemic therapy~* Participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis~* History of drug-induced psoriasis~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study~* Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment~* Concurrent or recent use of any biologic agent~* Have participated in any study with ixekizumab~* Received a live vaccination within 12 weeks prior to enrollment~* Serious disorder or illness other than psoriasis~* Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis~* Major surgery within 8 weeks of baseline, or will require surgery during the study~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg Ixekizumab Q2W (Type: EXPERIMENTAL): 160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
- 80 mg Ixekizumab Q4W (Type: EXPERIMENTAL): 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
- 80 mg Ixekizumab Q4W/Q2W (Type: EXPERIMENTAL): 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
- 80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort (Type: EXPERIMENTAL): 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
- 80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
- 80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): 160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete